Blocking GRB2 activity may therefore offer a biological and potentially attractive clinical alternative to stabilizing RAD51 filaments by inhibiting the PolQ ATPase stimulation by ssDNA by novobiocin, which has entered cancer clinical trials66. Here, GRB2 is linked to cancer.